Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Metastatic hormone-sensitive prostate cancer
Data

Cancers·Metastatic hormone-sensitive prostate cancer

DataMetastatic hormone-sensitive prostate cancer

Back to the Metastatic hormone-sensitive prostate cancer hub →105 connected records · 1 note

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

105

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Localised prostate cancer, intermediate risk
Shares Cambridge Prognostic Group (CPG 1 to 5), Ductal adenocarcinoma of the prostate, Other-cause mortality, TNM staging for prostate cancer, and what changed in the 9th edition and the tag subtype-page.
Cancer
Localised prostate cancer, very low and low risk
Shares Prostate Cancer UK, Cambridge Prognostic Group (CPG 1 to 5), Ductal adenocarcinoma of the prostate, Other-cause mortality and the tag subtype-page.
Cancer
Soft tissue sarcoma of the extremity (localised and advanced)
Shares Docetaxel, SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Endometrial cancer with no specific molecular profile
Shares PTEN loss, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
HR-positive metastatic breast cancer after CDK4/6 inhibitors
Shares PTEN loss, Capivasertib and the tag subtype-page.
Cancer
Myxofibrosarcoma
Shares Docetaxel, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Alveolar soft part sarcoma
Shares SBRT / SABR (stereotactic radiotherapy), IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Chromophobe renal cell carcinoma
Shares PTEN loss and the tag subtype-page.

technologies

Androgen deprivation & AR pathway inhibitors Cytotoxic chemotherapy Endocrine therapy (SERMs, AIs, SERDs)IMRT / IGRT (modern external beam)PI3K, AKT and mTOR inhibitors PSMA PET Radioligand therapy (beta emitters)SBRT / SABR (stereotactic radiotherapy)Small-molecule kinase inhibitors

targets

AKT Androgen receptor PIK3CA / PI3K-alpha PSMA PTEN

drugs

ApprovedSmall-molecule CYP17A1 inhibitor

Abiraterone acetate · Zytiga (generic)

ApprovedSmall-molecule AR antagonist

Apalutamide · Erleada

ApprovedSmall-molecule AKT inhibitor

Capivasertib · Truqap

ApprovedSmall-molecule AR antagonist

Darolutamide · Nubeqa

ApprovedGnRH antagonist depot

Degarelix · Firmagon

ApprovedCytotoxic chemotherapy (taxane)

Docetaxel · Taxotere (generic)

ApprovedSmall-molecule AR antagonist

Enzalutamide · Xtandi

ApprovedGnRH agonist depot

Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi

ApprovedRadioligand therapy (beta)

Lutetium-177 vipivotide tetraxetan · Pluvicto

ApprovedOral GnRH antagonist

Relugolix · Orgovyx

companies

AbbVie (incl. ImmunoGen, Capstan)Astellas AstraZeneca Bayer Ferring Pharmaceuticals Foresee Pharmaceuticals Johnson & Johnson MRC Clinical Trials Unit at UCL Novartis Oakwood Laboratories Pfizer (incl. Seagen)Sanofi Sumitomo Pharma (Myovant)Takeda Zydus Lifesciences

institutions

Prostate Cancer UK

terms

Androgen deprivation therapy (ADT)Cambridge Prognostic Group (CPG 1 to 5)Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk Genome-wide loss of heterozygosity (gLOH)Intermittent androgen deprivation (IAD)Metastasis-free survival (MFS)Oligometastatic disease Other-cause mortality Prostate cancer drugs in England: what NICE recommends, and what it refuses Prostate cancer programmes that failed, and what each failure taught PTEN loss Radiographic progression-free survival (rPFS)STAMPEDE's arms, and what each one answered TNM staging for prostate cancer, and what changed in the 9th edition What androgen deprivation costs: the side of hormone therapy the survival curves do not show

trials

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc ARANOTE ARASENS ARCHES CAPItello-281 CHAARTED (E3805)Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer ENZAMET GETUG-AFU 15 HERO KEYNOTE-991 LATITUDE ORIOLE PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)PEACE-1 PSMAddition Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents STAMPEDE STOMP Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC SWOG 9346 (intermittent androgen deprivation)This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in

roadmaps

Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch

ideas

Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later

people

key papers

ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Inherited DNA-repair gene mutations in men with metastatic prostate cancer LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer

biomarkers

AR amplification (gene and upstream enhancer)Homologous recombination repair gene mutation in prostate cancer PSMA expression by PET (PSMA-positive)PTEN alteration (sequencing) and PTEN loss (IHC)SPOP mutation

Notes

A word of caution about what stage IV means now. The ninth edition of TNM asks that a node or metastasis found on PSMA PET be written N1(PET) or M1(PET), because prostate is the malignancy most affected by stage migration: imaging now finds small-volume disease that older staging could not see, so a man diagnosed with metastatic disease on a PSMA PET may have much less cancer than a man given the same label before those scans existed, and the older survival figures were measured on the older label (Brierley 2026).

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-25. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file

Wikipedia

Prostate cancer#Metastatic disease

Sources & links

Wikipedia
NCCN Guidelines: Prostate Cancer
Brierley et al., International Journal of Cancer 2026: the 9th edition of the UICC TNM classification of malignant tumours, updates and rationale for change (prostate at section 10.1)

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Metastatic hormone-sensitive prostate cancer

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/prostate-mhspc/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id prostate-mhspc.

WebMCP tools registered on this page: onco_search, onco_get_entity.